MWNA
ONCY

Marshall Wace North America’s Oncolytics Biotech ONCY Stock Holding History

Marshall Wace North America’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-59,300
Closed -$141K – 1700
2020
Q4 		$141K Buy
+59,300
New +$142K ﹤0.01% 1249

Other funds holding ONCY

IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace North America's ONCY Position: Q1 2021 in Review

Marshall Wace North America sold out of Oncolytics Biotech (ONCY) in Q1 2021, closing a stake of 59,300 shares — an estimated $141K sold.

Marshall Wace North America first reported a position in ONCY in Q4 2020 and held it in 1 quarter. The position peaked at $141K in Q4 2020. 41 funds tracked by Wall St. Rank hold ONCY as of Q1 2021.

  • Marshall Wace North America reported no remaining Oncolytics Biotech position as of Q1 2021 after selling out during the quarter.
  • Marshall Wace North America sold 59,300 Oncolytics Biotech shares in Q1 2021, an estimated $141K.
  • Marshall Wace North America first reported a position in Oncolytics Biotech in Q4 2020 and held it in 1 quarter.
  • Marshall Wace North America's Oncolytics Biotech position peaked at $141K in Q4 2020.
  • 41 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.